Registry Study for Talimogene Laherparepvec

Completed

Conditions studied: Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial

In brief

A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects Who Previously Received Talimogene Laherparepvec in Amgen or BioVEX-Sponsored Clinical Trials

Key facts

Study ID

NCT02173171

Run by

Amgen

People needed

185

Starts

2010-04-27

Expected to finish

2021-09-23

Last updated by the study team

2021-09-30

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• All subjects must provide informed consent prior to initiation of any study activities.
• All subjects must have received at least one dose of talimogene laherparepvec on an Amgen or BioVEX-sponsored clinical trial for any tumor type and must have discontinued treatment and participation, including long-term follow-up (if applicable) in that trial.

You may not qualify if…

• Subjects currently receiving talimogene laherparepvec in Amgen or BioVEX-sponsored clinical trial.
• Subject currently participating, including for long-term follow-up (if applicable), in other Amgen-sponsored talimogene laherparepvec clinical trial.

Where it is running

• University of Arkansas for Medical Sciences — Little Rock, Arkansas, United States
• St Joseph Heritage Healthcare — Santa Rosa, California, United States
• University of Colorado Cancer Center — Aurora, Colorado, United States
• Florida Hospital Memorial Division — Daytona Beach, Florida, United States
• Baptist MD Anderson Cancer Center — Jacksonville, Florida, United States
• Mount Sinai Comprehensive Cancer Center — Miami Beach, Florida, United States
• H Lee Moffitt Cancer Center and Research Institute — Tampa, Florida, United States
• Oncology Specialists SC — Park Ridge, Illinois, United States
• Investigative Clinical Research of Indiana, LLC — Indianapolis, Indiana, United States
• Allina Health System dba Virginia Piper Cancer Institute — Minneapolis, Minnesota, United States
• Saint Louis University Hospital — St Louis, Missouri, United States
• Morristown Medical Center — Morristown, New Jersey, United States
• Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey, United States
• University of North Carolina Chapel Hill — Chapel Hill, North Carolina, United States
• Wake Forest Baptist Health Medical Center — Winston-Salem, North Carolina, United States
• Gabrail Cancer Center, LLC — Canton, Ohio, United States
• Providence Oncology and Hematology Care Eastside — Portland, Oregon, United States
• Greenville Health System Institute for Translational Oncology Research — Greenville, South Carolina, United States
• The West Clinic PC dba West Cancer Center — Germantown, Tennessee, United States
• Henry Joyce Cancer Center — Nashville, Tennessee, United States
• Mary Crowley Cancer Research — Dallas, Texas, United States
• University of Texas MD Anderson Cancer Center — Houston, Texas, United States
• Intermountain Medical Center — Murray, Utah, United States
• University of Utah Huntsman Cancer Institute — Salt Lake City, Utah, United States
• University of South Alabama Mitchell Cancer Institute — Mobile, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.